Search

Your search keyword '"Kiddle, Steven J."' showing total 7 results
Start Over Author "Kiddle, Steven J." Publisher springer science and business media llc
7 results on '"Kiddle, Steven J."'

2. Author Correction: Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk

Author

Jansen, Iris E., primary, Savage, Jeanne E., additional, Watanabe, Kyoko, additional, Bryois, Julien, additional, Williams, Dylan M., additional, Steinberg, Stacy, additional, Sealock, Julia, additional, Karlsson, Ida K., additional, Hägg, Sara, additional, Athanasiu, Lavinia, additional, Voyle, Nicola, additional, Proitsi, Petroula, additional, Witoelar, Aree, additional, Stringer, Sven, additional, Aarsland, Dag, additional, Almdahl, Ina S., additional, Andersen, Fred, additional, Bergh, Sverre, additional, Bettella, Francesco, additional, Bjornsson, Sigurbjorn, additional, Brækhus, Anne, additional, Bråthen, Geir, additional, de Leeuw, Christiaan, additional, Desikan, Rahul S., additional, Djurovic, Srdjan, additional, Dumitrescu, Logan, additional, Fladby, Tormod, additional, Hohman, Timothy J., additional, Jonsson, Palmi V., additional, Kiddle, Steven J., additional, Rongve, Arvid, additional, Saltvedt, Ingvild, additional, Sando, Sigrid B., additional, Selbæk, Geir, additional, Shoai, Maryam, additional, Skene, Nathan G., additional, Snaedal, Jon, additional, Stordal, Eystein, additional, Ulstein, Ingun D., additional, Wang, Yunpeng, additional, White, Linda R., additional, Hardy, John, additional, Hjerling-Leffler, Jens, additional, Sullivan, Patrick F., additional, van der Flier, Wiesje M., additional, Dobson, Richard, additional, Davis, Lea K., additional, Stefansson, Hreinn, additional, Stefansson, Kari, additional, Pedersen, Nancy L., additional, Ripke, Stephan, additional, Andreassen, Ole A., additional, and Posthuma, Danielle, additional

Published
2020
Full Text
View/download PDF

4. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic

Author

Hampel, Harald, O'Bryant, Sid E, Molinuevo, José L, Zetterberg, Henrik, Masters, Colin L, Lista, Simone, Kiddle, Steven J, Batrla, Richard, Blennow, Kaj, Kiddle, Steven [0000-0003-4350-7437], and Apollo - University of Cambridge Repository

Subjects
Early Diagnosis, Alzheimer Disease, Humans, Precision Medicine, Biomarkers
Abstract

Biomarker discovery and development for clinical research, diagnostics and therapy monitoring in clinical trials have advanced rapidly in key areas of medicine - most notably, oncology and cardiovascular diseases - allowing rapid early detection and supporting the evolution of biomarker-guided, precision-medicine-based targeted therapies. In Alzheimer disease (AD), breakthroughs in biomarker identification and validation include cerebrospinal fluid and PET markers of amyloid-β and tau proteins, which are highly accurate in detecting the presence of AD-associated pathophysiological and neuropathological changes. However, the high cost, insufficient accessibility and/or invasiveness of these assays limit their use as viable first-line tools for detecting patterns of pathophysiology. Therefore, a multistage, tiered approach is needed, prioritizing development of an initial screen to exclude from these tests the high numbers of people with cognitive deficits who do not demonstrate evidence of underlying AD pathophysiology. This Review summarizes the efforts of an international working group that aimed to survey the current landscape of blood-based AD biomarkers and outlines operational steps for an effective academic-industry co-development pathway from identification and assay development to validation for clinical use.

Published
2018

5. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk

Author

Jansen, Iris E., primary, Savage, Jeanne E., additional, Watanabe, Kyoko, additional, Bryois, Julien, additional, Williams, Dylan M., additional, Steinberg, Stacy, additional, Sealock, Julia, additional, Karlsson, Ida K., additional, Hägg, Sara, additional, Athanasiu, Lavinia, additional, Voyle, Nicola, additional, Proitsi, Petroula, additional, Witoelar, Aree, additional, Stringer, Sven, additional, Aarsland, Dag, additional, Almdahl, Ina S., additional, Andersen, Fred, additional, Bergh, Sverre, additional, Bettella, Francesco, additional, Bjornsson, Sigurbjorn, additional, Brækhus, Anne, additional, Bråthen, Geir, additional, de Leeuw, Christiaan, additional, Desikan, Rahul S., additional, Djurovic, Srdjan, additional, Dumitrescu, Logan, additional, Fladby, Tormod, additional, Hohman, Timothy J., additional, Jonsson, Palmi V., additional, Kiddle, Steven J., additional, Rongve, Arvid, additional, Saltvedt, Ingvild, additional, Sando, Sigrid B., additional, Selbæk, Geir, additional, Shoai, Maryam, additional, Skene, Nathan G., additional, Snaedal, Jon, additional, Stordal, Eystein, additional, Ulstein, Ingun D., additional, Wang, Yunpeng, additional, White, Linda R., additional, Hardy, John, additional, Hjerling-Leffler, Jens, additional, Sullivan, Patrick F., additional, van der Flier, Wiesje M., additional, Dobson, Richard, additional, Davis, Lea K., additional, Stefansson, Hreinn, additional, Stefansson, Kari, additional, Pedersen, Nancy L., additional, Ripke, Stephan, additional, Andreassen, Ole A., additional, and Posthuma, Danielle, additional

Published
2019
Full Text
View/download PDF

7. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic

Author

Hampel, Harald, O'Bryant, Sid E, Molinuevo, José L, Zetterberg, Henrik, Masters, Colin L, Lista, Simone, Kiddle, Steven J, Batrla, Richard, and Blennow, Kaj

Subjects
Early Diagnosis, Alzheimer Disease, Humans, Precision Medicine, Biomarkers, 3. Good health
Abstract

Biomarker discovery and development for clinical research, diagnostics and therapy monitoring in clinical trials have advanced rapidly in key areas of medicine - most notably, oncology and cardiovascular diseases - allowing rapid early detection and supporting the evolution of biomarker-guided, precision-medicine-based targeted therapies. In Alzheimer disease (AD), breakthroughs in biomarker identification and validation include cerebrospinal fluid and PET markers of amyloid-β and tau proteins, which are highly accurate in detecting the presence of AD-associated pathophysiological and neuropathological changes. However, the high cost, insufficient accessibility and/or invasiveness of these assays limit their use as viable first-line tools for detecting patterns of pathophysiology. Therefore, a multistage, tiered approach is needed, prioritizing development of an initial screen to exclude from these tests the high numbers of people with cognitive deficits who do not demonstrate evidence of underlying AD pathophysiology. This Review summarizes the efforts of an international working group that aimed to survey the current landscape of blood-based AD biomarkers and outlines operational steps for an effective academic-industry co-development pathway from identification and assay development to validation for clinical use.

Catalog

Books, media, physical & digital resources
See catalog results